Spinout Active LTD

Company profile

New Path Molecular Research Ltd

UK company 09412383, incorporated on 29 January 2015.

New Path Molecular

New Path Molecular Research Ltd is a UK company with status active founded in 2015 based in East of England.

Company number
09412383
Incorporated
29 Jan 2015
Companies House status
Active

Company identity

Browse spinouts
Founded / incorporated
29 January 2015

Company number 09412383

Verify at Companies House
Legal name
NEW PATH MOLECULAR RESEARCH LTD
Company type
LTD
Region
East of England
Registered address
Unknown
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

2 events
14 Aug
2026

Mortgage Create With Deed With Charge Number Charge Creation Date

Mortgage

MR01 | Transaction MzUzODc3NDgzOGFkaXF6a2N4

Published 19 Aug 2026 10:58

29 Jan
2015

Incorporated

Inception

Company registered at Companies House

Spinout profile

4 entries

Company description

New Path Molecular Research provides research services for flow chemistry projects.

New Path is chemistry driven: no biological mechanism has an impact on human health until a molecule is discovered to disrupt it It brings the best and most innovative chemistry to lanthipeptide discovery with a focus on drug resistant gram-negative bacteria and cancer therapy. They believe the impact that can be made by the best, most creative chemists, supported by the most sophisticated machine assisted chemistry tools has yet to be explored.

Project impact

Too early to say as yet.

New Path Molecular Research
2015
New Path Molecular Research
2015
New Path Molecular Research
2015
NEW PATH MOLECULAR RESEARCH LTD
2015

Public funding

2 awards
First funded
2024
Funded years
2024, 2025
Age at first award
9 years

Projects

2025 Collaborative R&D Lead participant

Development of PS Targeting Synthetic Protein Drug Conjugates As A Genetic Alteration Agnostic Cancer Therapy

1 May 2025 to 31 Oct 2026

Awarded
£547,972
Total cost £782,817

Pancreatic cancer (PDAC) patients face a lack of effective treatments, severe side effects from existing treatments and prolonged hospital stays, with limited impact on life expectancy. Globally, around 500,000 people are diagnosed annually (9,600 in UK), and this is expected to rise by 65% by 2040, one of the few cancers which is increasing in prevalence...

2024 Collaborative R&D Lead participant

Feasibility Study for a Novel Drug Conjugate Treatment for Pancreatic Cancer

1 May 2024 to 28 Feb 2025

Awarded
£99,835
Total cost £99,835

Pancreatic cancer (PDAC) patients face a lack of effective treatments, severe side effects from existing treatments and prolonged hospital stays, with limited impact on life expectancy. Globally, around 500,000 people are diagnosed annually (9,600 in UK), and this is expected to rise by 65% by 2040, one of the few cancers which is increasing in prevalence...

Product types

Collaborative R&D